2024 Agenda Revealed: 4th Wet AMD & Diabetic Eye Disease Drug Development Summit
With the recent FDA-approvals of Bayer’s Eylea HD 8mg as a durable long-term treatment for Wet AMD and Genentech’s Vabysmo for Retinal Vein Occlusion (RVO), now is the time to unite with fellow retinal vascular experts to harness novel ophthalmic innovations to accelerate long-lasting and efficacious drug development targeting neovascularization in the eye.
To aid this comes the return of the 4th Wet AMD & Diabetic Eye Disease Drug Development Summit to Boston, with exciting new data, fresh perspectives, and your shining opportunity to unite with fellow experts working on retinal vascular drug development.
The 18+ industry expert speakers include:
- Jayashree Sahni, Senior Global Program Clinical Head,Novartis
- Sergio Leal, Global Clinical Leader, Bayer
- Daniela Ferrara, Principal Medical & Ophthalmology Director, Genentech
- Pablo Velazquez-Martin,Senior Vice President, Clinical Research & Translational Medicine, Kodiak Sciences
- Kerrie Brady, Chief Executive Officer, OcuTerra Therapeutics
- Andrea Giani, Global Head of Medicine Retinal Health, Boehringer Ingelheim
Join 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the definitive industry-focused forum designed to allow preclinical and clinical R&D scientists to harness novel ophthalmic innovations to accelerate long-lasting and efficacious drug development targeting neovascularization in the eye.
For additional information on the program, tickets and more, visit: wet-amd-drug-development.com